Sunstone Life Science Fund III portfolio company Rigontec, the leader in RIG-I targeting RNA therapeutics, has announced the dosing of the first patient in a phase I/II study with intratumoral/intralesional administration of its lead compound RGT100 in solid tumors and lymphoma. RGT100 targets the retinoic acid-inducible gene I (RIG-I) pathway, one of the most essential pathways in the innate immune system to induce both immediate and long-term anti-tumor immunity.